## Giovanni Sette

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4013223/publications.pdf Version: 2024-02-01



CIOVANNI SETTE

#	Article	IF	CITATIONS
1	Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death and Differentiation, 2008, 15, 504-514.	11.2	1,511
2	Chemotherapy resistance of glioblastoma stem cells. Cell Death and Differentiation, 2006, 13, 1238-1241.	11.2	578
3	Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma. Journal of Neuroinflammation, 2011, 8, 32.	7.2	102
4	CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells. European Journal of Immunology, 2004, 34, 1930-1940.	2.9	95
5	Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer. Cell Death and Differentiation, 2014, 21, 1877-1888.	11.2	90
6	Inhibition of DNA Methylation Sensitizes Glioblastoma for Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Mediated Destruction. Cancer Research, 2005, 65, 11469-11477.	0.9	81
7	The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. Journal of Molecular Medicine, 2012, 90, 667-679.	3.9	54
8	Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells. Oncotarget, 2016, 7, 11332-11348.	1.8	49
9	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. Scientific Reports, 2017, 7, 43013.	3.3	44
10	Aloe-emodin exerts a potent anticancer and immunomodulatory activity on BRAF-mutated human melanoma cells. European Journal of Pharmacology, 2015, 762, 283-292.	3.5	43
11	Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer. Cell Death and Disease, 2015, 6, e1850-e1850.	6.3	42
12	Theratyping cystic fibrosis <i>in vitro</i> in ALI culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells. European Respiratory Journal, 2021, 58, 2100908.	6.7	39
13	A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors. Cell Death and Disease, 2019, 10, 529.	6.3	37
14	EGFR Inhibition Abrogates Leiomyosarcoma Cell Chemoresistance through Inactivation of Survival Pathways and Impairment of CSC Potential. PLoS ONE, 2012, 7, e46891.	2.5	36
15	Wharton's jelly mesenchymal stromal cells have contrasting effects on proliferation and phenotype of cancer stem cells from different subtypes of lung cancer. Experimental Cell Research, 2016, 345, 190-198.	2.6	27
16	Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. Journal of Experimental and Clinical Cancer Research, 2018, 37, 140.	8.6	27
17	A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells. Journal of Experimental and Clinical Cancer Research, 2019, 38, 373.	8.6	27
18	The kinase inhibitor SI113 induces autophagy and synergizes with quinacrine in hindering the growth of human glioblastoma multiforme cells. Journal of Experimental and Clinical Cancer Research, 2019, 38, 202.	8.6	26

#	Article	IF	CITATIONS
19	Conditionally reprogrammed cells (CRC) methodology does not allow the <i>in vitro</i> expansion of patientâ€derived primary and metastatic lung cancer cells. International Journal of Cancer, 2018, 143, 88-99.	5.1	22
20	Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts. Journal of Experimental and Clinical Cancer Research, 2013, 32, 91.	8.6	18
21	Natural compound Tetrocarcin-A downregulates Junctional Adhesion Molecule-A in conjunction with HER2 and inhibitor of apoptosis proteins and inhibits tumor cell growth. Cancer Letters, 2019, 440-441, 23-34.	7.2	17